Drug Profile
BMS 779788
Alternative Names: BMS-779788; BMS788; XL-652Latest Information Update: 03 Jan 2014
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Exelixis
- Developer Bristol-Myers Squibb
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 03 Jan 2014 No development reported - Phase-I for Atherosclerosis in Australia (PO)
- 23 Mar 2012 Phase-I development is ongoing
- 28 Feb 2009 Phase-I clinical trials in Atherosclerosis in Australia (PO)